Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

With $77M series B, condensates company Dewpoint aiming for proof of concept

By Paul Bonanos, Associate Editor
September 29, 2020 7:32 PM UTC

Dewpoint’s $77 million series B round affords the company “breathing room to make good decisions” as it chooses programs to develop and partner based on the science of biomolecular condensates, CEO Amir Nashat told BioCentury.

The company hopes to gain clinical proof of concept for at least one program, likely in oncology or neuroscience, as it continues to learn about how condensates are implicated in disease states...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Dewpoint Therapeutics Inc.